Holen Sie sich die Stockscreener-App
14.90
1.02%
0.15
Handel nachbörslich:
14.90
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock By Investing.com - Investing.com UK
Cantor Fitzgerald Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $21 - Moomoo
GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Q2 revenue up 21% to USD 22.8M - Medical Buyer
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroPace (NASDAQ:NPCE) Shares Gap DownHere's Why - MarketBeat
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up - Yahoo Finance Singapore
NeuroPace, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Neuropace earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Technical Reactions to NPCE Trends in Macro Strategies - Stock Traders Daily
NeuroPace Inc.: Q2 Earnings Snapshot - aol.com
NeuroPace Q2 Earnings Call Highlights - MarketBeat
NeuroPace Raises FY26 Sales Guidance Above Estimates - scanx.trade
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance - Investing News Network
NPCE: Q2 revenue up 17% to $22.8M; guidance raised; IGE FDA review ongoing with positive outlook - TradingView
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
NPCE: Revenue up 17% with strong RNS growth; guidance raised; IGE approval path remains active - TradingView
Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours - Investing.com
NeuroPace Q2 EPS beats estimates as revenue rises 17% to $22.8 million - scanx.trade
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
NeuroPace, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary - TradingView
NeuroPace, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NeuroPace, Inc. Revises Earnings Guidance for the Full Year of 2026 - marketscreener.com
Neuropace Inc (NASDAQ: NPCE) Share Price, NPCE Stock News, NPCE Share Price & Updates - Kalkine
Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NeuroPace, Inc. expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Neuropace Inc (NPCE) Stock News Today - TradingKey
Neuropace, Inc. (NPCE) Stock Analysis: A 45% Potential Upside Awaits Investors - DirectorsTalk Interviews
Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11 - Moomoo
NeuroPace (NPCE) Expected to Release Earnings on Tuesday - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
NPCE Q1 2026 Earnings: Narrower Net Loss Beats Expectations as Shares Decline 6.25%ROIC Trend Report - Vinanet
NPCE Q1 2026 Earnings: Narrower Loss Beats Estimates by 14.75%, Yet Shares Slip 6.25%Diluted EPS Report - Vinanet
Trading the Move, Not the Narrative: (NPCE) Edition - Stock Traders Daily
0.86%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):